research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
==== Donations to spouse's nonprofit organization ==== The Sacramento Bee reported that Jennifer Siebel Newsom's nonprofit organization The Representation Project had received more than $800,000 in donations from corporations that had lobbied the state government in recent years, including PG&E, AT&T, Comcast, and Kaiser Permanente. Siebel Newsom received $2.3 million in salary from the nonprofit since launching it in 2011. In 2021, Governor Newsom said that he saw no conflict in his wife's nonprofit accepting donations from companies that lobby his administration.
=== Iraq and Saddam Hussein === Writing for The Observer in April 2003, David Aaronovitch speculated that Galloway's support for Ba'athist Iraq and Saddam Hussein may have been based on "the belief that my enemy's enemy is my friend. Or, in the context of the modern world, any anti-American will do. When Iraq stopped being a friend of the West it became a friend of George's." According to Tam Dalyell, Galloway had been the "only one MP that I can recollect making speeches about human rights in Iraq" in the House of Commons. Galloway opposed the 1991 Gulf War and was critical of the effect that the subsequent sanctions had on the people of Iraq.
=== Journal articles === Bridge, D; Cunningham, C W; Schierwater, B; DeSalle, R; Buss, L W (15 September 1992). "Class-level relationships in the phylum Cnidaria: evidence from mitochondrial genome structure". Proceedings of the National Academy of Sciences. 89 (18): 8750–8753. Bibcode:1992PNAS...89.8750B. doi:10.1073/pnas.89.18.8750. PMC 49998. PMID 1356268. Bridge, D; Cunningham, CW; DeSalle, R; Buss, LW (July 1995). "Class-level relationships in the phylum Cnidaria: molecular and morphological evidence". Molecular Biology and Evolution. 12 (4): 679–689. doi:10.1093/oxfordjournals.molbev.a040246. PMID 7659022. Fautin, Daphne Gail (October 2002). "Reproduction of Cnidaria". Canadian Journal of Zoology. 80 (10): 1735–1754. Bibcode:2002CaJZ...80.1735F. doi:10.1139/z02-133. hdl:1808/5373. Mackie, G O (October 2002). "What's new in cnidarian biology?". Canadian Journal of Zoology. 80 (10): 1649–1653. Bibcode:2002CaJZ...80.1649M. doi:10.1139/z02-138. Schuchert, P. (27 April 2009). "Phylogenetic analysis of the Cnidaria". Journal of Zoological Systematics and Evolutionary Research. 31 (3): 161–173. doi:10.1111/j.1439-0469.1993.tb00187.x. Kass-Simon, G; Scappaticci, Jr., A A (October 2002). "The behavioral and developmental physiology of nematocysts". Canadian Journal of Zoology. 80 (10): 1772–1794. Bibcode:2002CaJZ...80.1772K. doi:10.1139/z02-135. J. Zrzavý (2001). "The interrelationships of metazoan parasites: a review of phylum- and higher-level hypotheses from recent morphological and molecular phylogenetic analyses". Folia Parasitologica. 48 (2): 81–103.
The facility is now heavily damaged, and it soon becomes clear that a new alien race, Race X, has exploited the situation to mount a localized invasion, attacking both human and Xen forces in Black Mesa indiscriminately. Fighting between the black operations units and Race X quickly intensifies. Shephard encounters more stranded Marine units in the wreckage of Black Mesa, and attempts to reach an unknown exit route, encountering heavy resistance from Race X and black operations units. A surviving Black Mesa security guard reveals to Shephard that the black operators intend to detonate a tactical nuclear weapon in the base, thereby totally sealing it off and killing everything in it. After neutralizing the black ops unit guarding the device, Shephard disarms it and proceeds to a nearby storage facility to attempt another escape. As Shephard departs, the G-Man rearms the nuclear device. The storage facility has become a battleground between Race X and the black operation units. Although Shephard manages to evade them, he is informed by another security guard that something very large is coming through an alien portal blocking the exit path. At the portal, Shephard discovers a gene worm, a massive creature facilitating the Race X invasion. Shephard is able to wound the creature enough to force it back through the wormhole, but immediately afterwards he is teleported onto an Osprey by the G-Man. As the G-Man congratulates Shephard on his accomplishments, the nuclear device detonates in the background, destroying Black Mesa.
=== Training === Endocrinologists are specialists of internal medicine or pediatrics. Reproductive endocrinologists deal primarily with problems of fertility and menstrual function—often training first in obstetrics. Most qualify as an internist, pediatrician, or gynecologist for a few years before specializing, depending on the local training system. In the U.S. and Canada, training for board certification in internal medicine, pediatrics, or gynecology after medical school is called residency. Further formal training to subspecialize in adult, pediatric, or reproductive endocrinology is called a fellowship. Typical training for a North American endocrinologist involves 4 years of college, 4 years of medical school, 3 years of residency, and 2 years of fellowship. In the US, adult endocrinologists are board certified by the American Board of Internal Medicine (ABIM) or the American Osteopathic Board of Internal Medicine (AOBIM) in Endocrinology, Diabetes and Metabolism.
Sources: en.wikipedia.org
The origin and first recorded use of the term megacap (or any of its various spellings), in relation to stock capitalization, is unclear. It dates back to at least 1997, if not earlier. The S&P 100 was launched on June 15, 1983. The Russell Top 200 Index was launched on September 1, 1992. The Fidelity Mega Cap Stock Fund's inception was on December 28, 1998. The Russell Top 50 Mega Cap Index was launched on January 1, 2005. Also in 2005, investment advisory executive Richard Imperiale noted that some investors were classifying "the top 10 percent of companies by market cap" into a mega cap segment of the stock market. In 2009, the third edition of Stock Investing For Dummies defined mega caps (and ultra caps) as companies with market caps over $50 billion. Subsequent editions used that definition until 2020, when the sixth edition redefined them as having market caps over $200 billion. The 2023 version, retitled Investing in Stocks For Dummies, used the same definition as the sixth edition. The Morningstar US Mega Cap Index was established on March 31, 2011. In 2011, Investing Demystified defined mega-caps as companies with market caps of at least $25 billion, whereas in the same year, The Complete Idiot's Guide to Stock Investing defined them as having market caps at least $50 billion. That's equivalent to $34 billion and $69 billion, respectively, in 2024 using GDP deflator adjustment. In 2014, Asset Allocation Demystified stated that a typical mega cap company had a market cap of over $50 billion. The S&P 500 Top 50 Index was launched on November 30, 2015.
=== Brain growth === Neuroanatomical studies and the association between autism and teratogens strongly suggest that autism affects brain development soon after conception. This anomaly appears to start a cascade of pathological events in the brain that are significantly influenced by environmental factors. Just after birth, the brains of children with autism tend to grow faster than usual, followed by normal or relatively slower growth in childhood. It is unknown whether early brain overgrowth occurs in all children with autism. It appears to be most prominent in the frontal and temporal lobes, which are associated with higher cognitive specializations such as social cognition, and language development. Hypotheses for the cellular and molecular bases of pathological early overgrowth include an excess of neurons that causes local overconnectivity in key brain regions, and disturbed neuronal migration during early gestation.
Deoxyhypusine synthase (DHPS, DHS) catalyzes the cleavage of the polyamine spermidine and transfer of its 4-aminobutyl moiety to the ε-amino group of one specific lysine residue of the eIF-5A precursor to form deoxyhypusine and 1,3-diaminopropane. This step is universal among eukaryotes and archaea. Deoxyhypusine hydroxylase mediates the formation of hypusine by addition of a hydroxyl group to the deoxyhypusine residue. This step is universal among eukaryotes, but absent in some archaea (the Euryarchaea). Inhibition of DHPS causes cell cycle arrest in all tested archaea (Sulfolobus, Halobacterium halobium, Haloferax mediterranei). An excess of hypusine was found in the urine of children and patients with familial hyperlysinemia. Hypusine was first isolated from bovine brain by Japanese scientists Shiba et al. in 1971. The name hypusine indicates that the molecule comprises moieties of hydroxyputrescine and lysine.
=== Temporal low-voltage irregular delta wave === Temporal low-voltage irregular delta wave activity has been commonly detected in patients with ischemic brain diseases, particularly in association with small ischemic lesions and is seen to be indicative of early-stage cerebrovascular damage.
== Overdose == Overdosing of up to 80 times the usual therapeutic dose has been described. Expected symptoms include severe hypotension (low blood pressure) and reflex tachycardia. Bradycardia (slow heartbeat) can also occur due to blockage of calcium channels in the atrioventricular node of the heart. There is no treatment besides monitoring blood pressure and heart function. Dialysis is likely ineffective because most of the lercanidipine is bound to blood plasma proteins and lipid membranes of cells.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.